Clinical Proof of Concept of Setidegrasib (ASP3082)

• Astellas’ strategy to strengthen its R&D pipeline and deliver meaningful value to patients
• Clinical proof of concept of Setidegrasib in advanced non small cell lung cancer and pancreatic cancer
• Beyond Setidegrasib: defining the next steps for targeted protein degradation

Speakers:

Itsuro Nagase

Senior Vice President, Head of Primary Focus Lead - Targeted Protein Degradation

Astellas Pharma